These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 15592886

  • 1. Therapeutic effects of dengue 2 virus capsid protein and staphylococcal nuclease fusion protein on dengue-infected cell cultures.
    Qin CF, Qin E, Yu M, Chen SP, Jiang T, Deng YQ, Duan HY, Zhao H.
    Arch Virol; 2005 Apr; 150(4):659-69. PubMed ID: 15592886
    [Abstract] [Full Text] [Related]

  • 2. [Capsid-targeted viral inactivation for dengue virus infection].
    Qin CF, Jiang T, Chen SP, Yu M, Qin ED.
    Wei Sheng Wu Xue Bao; 2005 Feb; 45(1):111-5. PubMed ID: 15847175
    [Abstract] [Full Text] [Related]

  • 3. Capsid-targeted viral inactivation can destroy dengue 2 virus from within in vitro.
    Qin CF, Qin ED.
    Arch Virol; 2006 Feb; 151(2):379-85. PubMed ID: 16155726
    [Abstract] [Full Text] [Related]

  • 4. Development of cell lines stably expressing staphylococcal nuclease fused to dengue 2 virus capsid protein for CTVI.
    Qin CF, Qin ED.
    Acta Biochim Biophys Sin (Shanghai); 2004 Aug; 36(8):577-82. PubMed ID: 15295652
    [Abstract] [Full Text] [Related]

  • 5. In vitro inhibition of the replication of classical swine fever virus by capsid-targeted virus inactivation.
    Wang YF, Wang ZH, Li Y, Zhang XJ, Sun Y, Li M, Qiu HJ.
    Antiviral Res; 2010 Feb; 85(2):422-4. PubMed ID: 19857524
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of replication of classical swine fever virus in a stable cell line by the viral capsid and Staphylococcus aureus nuclease fusion protein.
    Zhou B, Liu K, Wei JC, Mao X, Chen PY.
    J Virol Methods; 2010 Jul; 167(1):79-83. PubMed ID: 20304012
    [Abstract] [Full Text] [Related]

  • 7. Capsid-targeted viral inactivation can eliminate the production of infectious murine leukemia virus in vitro.
    VanBrocklin M, Federspiel MJ.
    Virology; 2000 Feb 01; 267(1):111-23. PubMed ID: 10648188
    [Abstract] [Full Text] [Related]

  • 8. In vitro inhibition of Japanese encephalitis virus replication by capsid-targeted virus inactivation.
    Pang R, He DN, Zhou B, Liu K, Zhao J, Zhang XM, Chen PY.
    Antiviral Res; 2013 Mar 01; 97(3):369-75. PubMed ID: 23321201
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic effect of Gag-nuclease fusion protein on retrovirus-infected cell cultures.
    Schumann G, Qin L, Rein A, Natsoulis G, Boeke JD.
    J Virol; 1996 Jul 01; 70(7):4329-37. PubMed ID: 8676455
    [Abstract] [Full Text] [Related]

  • 10. High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli.
    Jaiswal S, Khanna N, Swaminathan S.
    Protein Expr Purif; 2004 Jan 01; 33(1):80-91. PubMed ID: 14680965
    [Abstract] [Full Text] [Related]

  • 11. A small molecule fusion inhibitor of dengue virus.
    Poh MK, Yip A, Zhang S, Priestle JP, Ma NL, Smit JM, Wilschut J, Shi PY, Wenk MR, Schul W.
    Antiviral Res; 2009 Dec 01; 84(3):260-6. PubMed ID: 19800368
    [Abstract] [Full Text] [Related]

  • 12. Targeting a host process as an antiviral approach against dengue virus.
    Sayce AC, Miller JL, Zitzmann N.
    Trends Microbiol; 2010 Jul 01; 18(7):323-30. PubMed ID: 20452219
    [Abstract] [Full Text] [Related]

  • 13. Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach.
    Melino S, Paci M.
    FEBS J; 2007 Jun 01; 274(12):2986-3002. PubMed ID: 17509079
    [Abstract] [Full Text] [Related]

  • 14. Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors.
    Khanam S, Khanna N, Swaminathan S.
    Vaccine; 2006 Oct 30; 24(42-43):6513-25. PubMed ID: 16860446
    [Abstract] [Full Text] [Related]

  • 15. [Recombinant envelope glycoprotein domain III of dengue virus inhibit virus infection].
    Lu P, Wei Y, Cao SC, Li JD, Liu QZ, Zhang QF, Li C, Miao F, Zhang S, Hang XT, Liang MF, Li DX.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Jun 30; 22(3):177-9. PubMed ID: 19031695
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic effects of duck Tembusu virus capsid protein fused with staphylococcal nuclease protein to target Tembusu infection in vitro.
    Zhang X, Jia R, Pan Y, Wang M, Chen S, Zhu D, Liu M, Zhao X, Yang Q, Wu Y, Zhang S, Liu Y, Zhang L, Yin Z, Jing B, Huang J, Tian B, Pan L, Yu Y, Ur Rehman M, Cheng A.
    Vet Microbiol; 2019 Aug 30; 235():295-300. PubMed ID: 31383316
    [Abstract] [Full Text] [Related]

  • 17. Targeting of a nuclease to murine leukemia virus capsids inhibits viral multiplication.
    Natsoulis G, Seshaiah P, Federspiel MJ, Rein A, Hughes SH, Boeke JD.
    Proc Natl Acad Sci U S A; 1995 Jan 17; 92(2):364-8. PubMed ID: 7831291
    [Abstract] [Full Text] [Related]

  • 18. Quantum dots encapsulated with amphiphilic alginate as bioprobe for fast screening anti-dengue virus agents.
    Wang CH, Hsu YS, Peng CA.
    Biosens Bioelectron; 2008 Dec 01; 24(4):1018-25. PubMed ID: 18801653
    [Abstract] [Full Text] [Related]

  • 19. Analysis of the steps involved in Dengue virus entry into host cells.
    Hung SL, Lee PL, Chen HW, Chen LK, Kao CL, King CC.
    Virology; 1999 Apr 25; 257(1):156-67. PubMed ID: 10208929
    [Abstract] [Full Text] [Related]

  • 20. High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice.
    Zhang ZS, Yan YS, Weng YW, Huang HL, Li SQ, He S, Zhang JM.
    J Virol Methods; 2007 Aug 25; 143(2):125-31. PubMed ID: 17532481
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.